Abstract
T HE value of estrogenic preparations in the treatment of the menopausal syndrome is firmly established. Ever since chemically pure estrogens became available, the medical profession has sought earnestly for compounds which, when given orally, have the distinction of high potency, good tolerability, and economy. In 1938, Inhoffen and Hohlweg3 prepared a derivative of estradiol by replacing the hydrogen atom at carbon atom 17 with an ethinyl group. It is claimed that the new compound fulfills the requirements of great effectiveness when administered by mouth, of comparative absence of unpleasant “side reactions, and of inexpensiveness. Clinical results with ethinyl estradiol in climacteric patients have been described only by a limited number of investigators ; hence a report of further experiences along these lines seems warranted.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
